# CEO Review: Med/Low security remediation (S7–S15)

**Date:** 2026-08-21  
**Status:** **Accept with conditions**  
**Requirements:** [`.docs/requirements/security-med-low-s7-s15.md`](../requirements/security-med-low-s7-s15.md)  
**Prerequisite:** High S1–S6 Met

## Ask

Should we invest in Med/Low findings now that High is Accept?

## Verdict

| Field | Value |
|-------|--------|
| **Verdict** | **Accept with conditions** |
| **Priority** | **P1 after High merge** — required for credible “production” language |
| **Ambition** | Right-sized: no cookie rewrite; phased quick wins first |

## Why

High closed the isolation/AuthN disasters. Remaining items are what questionnaires and pen-testers hit next: unauthenticated validate, upload bombs, published Postgres, catalog leakage, brute force. Shipping P1 quickly is high ROI.

## Conditions

| ID | Condition |
|----|-----------|
| **C1** | **OQ-S10 Decided Yes:** P4 includes httpOnly cookie / BFF — treat as real AuthN work, not docs-only. |
| **C2** | Phase order P1→P2→P3→P4; P1–P2 can ship before cookies if reviews allow. |
| **C3** | Do not claim whole-product production-ready until P1+P2 Met, S12 prod profile exists, and cookie cutover plan is clear. |
| **C4** | Keep High S1–S6 behavior unchanged. |
| **C5** | S14 Decided: drop biotype/temperature from write-back. |
| **C6** | Empty containers: never commit barren tube/plate/box (OQ-S11a). |

## Decision

**Proceed** with OQs stamped; implement **P1** after any review re-confirm on P4 cookie scope.
